Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Jun 15, 2026; 18(6): 117308
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.117308
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.117308
Table 1 Association between KRAS mutation status and clinicopathological features, n (%)
| Clinicopathological feature | Total (n = 87) | KRAS mutant (n = 39) | KRAS wild-type (n = 48) | χ² value | P value |
| Tumor location | 4.64 | 0.098 | |||
| Left colon | 21 (24.14) | 7 (17.95) | 14 (29.17) | ||
| Rectum | 46 (52.87) | 19 (48.72) | 27 (56.25) | ||
| Right colon | 20 (22.99) | 13 (33.33) | 7 (14.58) | ||
| Differentiation grade | 4.52 | 0.034 | |||
| Well/moderate | 72 (82.76) | 36 (92.31) | 36 (75.00) | ||
| Poor | 15 (17.24) | 3 (7.69) | 12 (25.00) | ||
| Lymphovascular invasion | 2.86 | 0.091 | |||
| Absent | 51 (58.62) | 19 (48.72) | 32 (66.67) | ||
| Present | 36 (41.38) | 20 (51.28) | 16 (33.33) | ||
| Perineural Invasion | 17.132 | < 0.001 | |||
| Absent | 75 (86.21) | 27 (69.23) | 48 (100.00) | ||
| Present | 12 (13.79) | 12 (30.77) | 0 (0.00) | ||
| Preoperative pathology | 0.06 | 0.811 | |||
| Adenocarcinoma (non-special) | 82 (94.25) | 36 (92.31) | 46 (95.83) | ||
| Mucinous adenocarcinoma | 5 (5.75) | 3 (7.69) | 2 (4.17) | ||
| T stage | 2.60 | 0.107 | |||
| T1 + T2 | 5 (5.75) | 0 (0.00) | 5 (10.42) | ||
| T3 + T4 | 82 (94.25) | 39 (100.00) | 43 (89.58) | ||
| N stage | 11.31 | < 0.001 | |||
| N0 | 12 (13.79) | 0 (0.00) | 12 (25.00) | ||
| N1 + N2 | 75 (86.21) | 39 (100.00) | 36 (75.00) | ||
| M stage | 7.22 | 0.007 | |||
| M0 | 71 (81.61) | 27 (69.23) | 44 (91.67) | ||
| M1 | 16 (18.39) | 12 (30.77) | 4 (8.33) | ||
| Tumor number | 17.13 | < 0.001 | |||
| Solitary | 75 (86.21) | 27 (69.23) | 48 (100.00) | ||
| Multiple (≥ 2) | 12 (13.79) | 12 (30.77) | 0 (0.00) | ||
| Maximum tumor diameter | 21.39 | < 0.001 | |||
| < 5 cm | 32 (36.78) | 4 (10.26) | 28 (58.33) | ||
| ≥ 5 cm | 55 (63.22) | 35 (89.74) | 20 (41.67) | ||
| Preoperative tumor markers | 16.29 | < 0.001 | |||
| Normal | 65 (74.71) | 21 (53.85) | 44 (91.67) | ||
| Elevated | 22 (25.29) | 18 (46.15) | 4 (8.33) | ||
| Microsatellite | 0.03 | 0.872 | |||
| Microsatellite stable | 81 (93.10) | 37 (94.87) | 44 (91.67) | ||
| Microsatellite instability | 6 (6.90) | 2 (5.13) | 4 (8.33) |
Table 2 Association between PIK3CA mutation status and clinicopathological features, n (%)
| Clinicopathological feature | Total (n = 87) | PIK3CA mutant (n = 12) | PIK3CA wild-type (n = 75) | χ² value | P value |
| Tumor location | - | 0.134 | |||
| Left colon | 21 (24.14) | 6 (50.00) | 15 (20.00) | ||
| Rectum | 46 (52.87) | 4 (33.33) | 42 (56.00) | ||
| Right colon | 20 (22.99) | 2 (16.67) | 18 (24.00) | ||
| Differentiation grade | 1.67 | 0.197 | |||
| Well/moderate | 72 (82.76) | 12 (100.00) | 60 (80.00) | ||
| Poor | 15 (17.24) | 0 (0.00) | 15 (20.00) | ||
| Lymphovascular invasion | 0.09 | 0.769 | |||
| Absent | 51 (58.62) | 8 (66.67) | 43 (57.33) | ||
| Present | 36 (41.38) | 4 (33.33) | 32 (42.67) | ||
| Perineural invasion | 1.08 | 0.298 | |||
| Absent | 75 (86.21) | 12 (100.00) | 63 (84.00) | ||
| Present | 12 (13.79) | 0 (0.00) | 12 (16.00) | ||
| Preoperative pathology | - | 0.533 | |||
| Adenocarcinoma (non-special) | 82 (94.25) | 11 (91.67) | 71 (94.67) | ||
| Mucinous adenocarcinoma | 5 (5.75) | 1 (8.33) | 4 (5.33) | ||
| T stage | - | 1.000 | |||
| T1 + T2 | 5 (5.75) | 0 (0.00) | 5 (6.67) | ||
| T3 + T4 | 82 (94.25) | 12 (100.00) | 70 (93.33) | ||
| N stage | 2.77 | 0.096 | |||
| N0 | 75 (86.21) | 8 (66.67) | 67 (89.33) | ||
| N1 + N2 | 12 (13.79) | 4 (33.33) | 8 (10.67) | ||
| M stage | 1.88 | 0.171 | |||
| M0 | 71 (81.61) | 12 (100.00) | 59 (78.67) | ||
| M1 | 16 (18.39) | 0 (0.00) | 16 (21.33) | ||
| Tumor number | 2.77 | 0.096 | |||
| Solitary | 75 (86.21) | 8 (66.67) | 67 (89.33) | ||
| Multiple (≥ 2) | 12 (13.79) | 4 (33.33) | 8 (10.67) | ||
| Maximum tumor diameter | 6.37 | 0.012 | |||
| < 5 cm | 32 (36.78) | 0 (0.00) | 32 (42.67) | ||
| ≥ 5 cm | 55 (63.22) | 12 (100.00) | 43 (57.33) | ||
| Preoperative tumor markers | 0.11 | 0.739 | |||
| Normal | 65 (74.71) | 8 (66.67) | 57 (76.00) | ||
| Elevated | 22 (25.29) | 4 (33.33) | 18 (24.00) | ||
| Microsatellite | - | 0.590 | |||
| Microsatellite stable | 81 (93.10) | 12 (100.00) | 69 (92.00) | ||
| Microsatellite instability | 6 (6.90) | 0 (0.00) | 6 (8.00) |
Table 3 Association between FBXW7 mutation status and clinicopathological features, n (%)
| Clinicopathological feature | Total (n = 87) | FBXW7 mutant (n = 24) | FBXW7 wild-type (n = 63) | χ² value | P value |
| Tumor location | 14.20 | < 0.001 | |||
| Left colon | 21 (24.14) | 4 (16.67) | 17 (26.98) | ||
| Rectum | 46 (52.87) | 20 (83.33) | 26 (41.27) | ||
| Right colon | 20 (22.99) | 0 (0.00) | 20 (31.75) | ||
| Differentiation grade | 0.01 | 1.000 | |||
| Well/moderate | 72 (82.76) | 20 (83.33) | 52 (82.54) | ||
| Poor | 15 (17.24) | 4 (16.67) | 11 (17.46) | ||
| Lymphovascular invasion | 0.88 | 0.347 | |||
| Absent | 51 (58.62) | 16 (66.67) | 35 (55.56) | ||
| Present | 36 (41.38) | 8 (33.33) | 28 (44.44) | ||
| Perineural invasion | 0.02 | 0.895 | |||
| Absent | 75 (86.21) | 20 (83.33) | 55 (87.30) | ||
| Present | 12 (13.79) | 4 (16.67) | 8 (12.70) | ||
| Preoperative pathology | 0.02 | 0.901 | |||
| Adenocarcinoma (non-special) | 82 (94.25) | 22 (91.67) | 60 (95.24) | ||
| Mucinous adenocarcinoma | 5 (5.75) | 2 (8.33) | 3 (4.76) | ||
| T stage | 0.82 | 0.365 | |||
| T1 + T2 | 5 (5.75) | 0 (0.00) | 5 (7.94) | ||
| T3 + T4 | 82 (94.25) | 24 (100.00) | 58 (92.06) | ||
| N stage | 0.02 | 0.895 | |||
| N0 | 12 (13.79) | 4 (16.67) | 8 (12.70) | ||
| N1 + N2 | 75 (86.21) | 20 (83.33) | 55 (87.30) | ||
| M stage | 3.65 | 0.056 | |||
| M0 | 71 (81.61) | 16 (66.67) | 55 (87.30) | ||
| M1 | 16 (18.39) | 8 (33.33) | 8 (12.70) | ||
| Tumor number | 3.82 | 0.051 | |||
| Solitary | 75 (86.21) | 24 (100.00) | 51 (80.95) | ||
| Multiple (≥ 2) | 12 (13.79) | 0 (0.00) | 12 (19.05) | ||
| Maximum tumor diameter | 5.77 | 0.016 | |||
| < 5 cm | 32 (36.78) | 4 (16.67) | 28 (44.44) | ||
| ≥ 5 cm | 55 (63.22) | 20 (83.33) | 35 (55.56) | ||
| Preoperative tumor markers | 2.87 | 0.090 | |||
| Normal | 65 (74.71) | 21 (87.50) | 44 (69.84) | ||
| Elevated | 22 (25.29) | 3 (12.50) | 19 (30.16) | ||
| Microsatellite | 1.20 | 0.274 | |||
| Microsatellite stable | 81 (93.10) | 24 (100.00) | 57 (90.48) | ||
| Microsatellite instability | 6 (6.90) | 0 (0.00) | 6 (9.52) |
Table 4 Association between TP53 mutation status and clinicopathological features, n (%)
| Clinicopathological feature | Total (n = 87) | TP53 mutant (n = 56) | TP53 wild-type (n = 31) | χ² value | P value |
| Tumor location | 1.86 | 0.394 | |||
| Left colon | 21 (24.14) | 11 (19.64) | 10 (32.26) | ||
| Rectum | 46 (52.87) | 32 (57.14) | 14 (45.16) | ||
| Right colon | 20 (22.99) | 13 (23.21) | 7 (22.58) | ||
| Differentiation grade | 1.93 | 0.165 | |||
| Well/moderate | 72 (82.76) | 44 (78.57) | 28 (90.32) | ||
| Poor | 15 (17.24) | 12 (21.43) | 3 (9.68) | ||
| Lymphovascular invasion | 10.63 | 0.001 | |||
| Absent | 51 (58.62) | 40 (71.43) | 11 (35.48) | ||
| Present | 36 (41.38) | 16 (28.57) | 20 (64.52) | ||
| Perineural invasion | 6.01 | 0.014 | |||
| Absent | 75 (86.21) | 44 (78.57) | 31 (100.00) | ||
| Present | 12 (13.79) | 12 (21.43) | 0 (0.00) | ||
| Preoperative pathology | 0.07 | 0.786 | |||
| Adenocarcinoma (non-special) | 82 (94.25) | 52 (92.86) | 30 (96.77) | ||
| Mucinous adenocarcinoma | 5 (5.75) | 4 (7.14) | 1 (3.23) | ||
| T stage | 1.52 | 0.218 | |||
| T1 + T2 | 5 (5.75) | 5 (8.93) | 0 (0.00) | ||
| T3 + T4 | 82 (94.25) | 51 (91.07) | 31 (100.00) | ||
| N stage | 0.00 | 1.000 | |||
| N0 | 12 (13.79) | 8 (14.29) | 4 (12.90) | ||
| N1 + N2 | 75 (86.21) | 48 (85.71) | 27 (87.10) | ||
| M stage | 1.76 | 0.184 | |||
| M0 | 71 (81.61) | 48 (85.71) | 23 (74.19) | ||
| M1 | 16 (18.39) | 8 (14.29) | 8 (25.81) | ||
| Tumor number | 4.38 | 0.036 | |||
| Solitary | 75 (86.21) | 52 (92.86) | 23 (74.19) | ||
| Multiple (≥ 2) | 12 (13.79) | 4 (7.14) | 8 (25.81) | ||
| Maximum tumor diameter | 2.49 | 0.114 | |||
| < 5 cm | 32 (36.78) | 24 (42.86) | 8 (25.81) | ||
| ≥ 5 cm | 55 (63.22) | 32 (57.14) | 23 (74.19) | ||
| Preoperative tumor markers | 13.60 | < 0.001 | |||
| Normal | 65 (74.71) | 49 (87.50) | 16 (51.61) | ||
| Elevated | 22 (25.29) | 7 (12.50) | 15 (48.39) | ||
| Microsatellite | 8.82 | 0.003 | |||
| Microsatellite stable | 81 (93.10) | 56 (100.00) | 25 (80.65) | ||
| Microsatellite instability | 6 (6.90) | 0 (0.00) | 6 (19.35) |
Table 5 Association between genetic mutations, clinicopathological features and prognosis (3-year survival), n (%)
| Variable | Total (n = 87) | Death (n = 32) | Survival (n = 55) | χ² value | P value |
| Gender | 0.17 | 0.681 | |||
| Female | 24 (27.59) | 8 (25.00) | 16 (29.09) | ||
| Male | 63 (72.41) | 24 (75.00) | 39 (70.91) | ||
| Age | 3.15 | 0.076 | |||
| < 60 years | 20 (22.99) | 4 (12.50) | 16 (29.09) | ||
| ≥ 60 years | 67 (77.01) | 28 (87.50) | 39 (70.91) | ||
| KRAS mutation | 6.39 | 0.011 | |||
| Mutant | 39 (44.83) | 20 (62.50) | 19 (34.55) | ||
| Wild-type | 48 (55.17) | 12 (37.50) | 36 (65.45) | ||
| PIK3CA mutation | 0.00 | 1.000 | |||
| Mutant | 12 (13.79) | 4 (12.50) | 8 (14.55) | ||
| Wild-type | 75 (86.21) | 28 (87.50) | 47 (85.45) | ||
| FBXW7 mutation | 2.49 | 0.115 | |||
| Mutant | 24 (27.59) | 12 (37.50) | 12 (21.82) | ||
| Wild-type | 63 (72.41) | 20 (62.50) | 43(78.18) | ||
| TP53 mutation | 2.49 | 0.114 | |||
| Mutant | 56 (64.37) | 24 (75.00) | 32 (58.18) | ||
| Wild-type | 31 (35.63) | 8 (25.00) | 23 (41.82) | ||
| Diabetes | 12.32 | < 0.001 | |||
| Absent | 71 (81.61) | 20 (62.50) | 51 (92.73) | ||
| Present | 16 (18.39) | 12 (37.50) | 4 (7.27) | ||
| Hypertension | 6.39 | 0.011 | |||
| Absent | 48 (55.17) | 12 (37.50) | 36 (65.45) | ||
| Present | 39 (44.83) | 20 (62.50) | 19 (34.55) | ||
| Hyperlipidemia | 1.17 | 0.279 | |||
| Absent | 71 (81.61) | 28 (87.50) | 43 (78.18) | ||
| Present | 16 (18.39) | 4 (12.50) | 12 (21.82) | ||
| Smoking | 1.17 | 0.280 | |||
| Absent | 63 (72.41) | 21 (65.62) | 42 (76.36) | ||
| Present | 24 (27.59) | 11 (34.38) | 13 (23.64) | ||
| Alcohol use | 2.46 | 0.116 | |||
| Absent | 62 (71.26) | 26 (81.25) | 36 (65.45) | ||
| Present | 25 (28.74) | 6 (18.75) | 19 (34.55) | ||
| Tumor location | 0.94 | 0.625 | |||
| Left colon | 21 (24.14) | 8 (25.00) | 13 (23.64) | ||
| Rectum | 46 (52.87) | 15 (46.88) | 31 (56.36) | ||
| Right colon | 20 (22.99) | 9 (28.12) | 11 (20.00) | ||
| Differentiation grade | 0.80 | 0.372 | |||
| Well/moderate | 72 (82.76) | 28 (87.50) | 44 (80.00) | ||
| Poor | 15 (17.24) | 4 (12.50) | 11 (20.00) | ||
| Lymphovascular invasion | 5.60 | 0.018 | |||
| Absent | 51 (58.62) | 24 (75.00) | 27 (49.09) | ||
| Present | 36 (41.38) | 8 (25.00) | 28 (50.91) | ||
| Perineural invasion | 0.00 | 1.000 | |||
| Absent | 75 (86.21) | 28 (87.50) | 47 (85.45) | ||
| Present | 12 (13.79) | 4 (12.50) | 8 (14.55) | ||
| Preoperative pathology | 0.00 | 1.000 | |||
| Adenocarcinoma (non-special) | 82 (94.25) | 30 (93.75) | 52 (94.55) | ||
| Mucinous adenocarcinoma | 5 (5.75) | 2 (6.25) | 3 (5.45) | ||
| T stage | 1.64 | 0.201 | |||
| T1 + T2 | 5 (5.75) | 0 (0.00) | 5 (9.09) | ||
| T3 + T4 | 82 (94.25) | 32 (100.00) | 50 (90.91) | ||
| N stage | 6.37 | 0.012 | |||
| N0 | 12 (13.79) | 0 (0.00) | 12 (21.82) | ||
| N1 + N2 | 75 (86.21) | 32 (100.00) | 43 (78.18) | ||
| M stage | 1.47 | 0.225 | |||
| M0 | 71 (81.61) | 24 (75.00) | 47 (85.45) | ||
| M1 | 16 (18.39) | 8 (25.00) | 8 (14.55) | ||
| Surgical approach | 5.93 | 0.015 | |||
| Laparoscopic | 60 (68.97) | 17 (53.12) | 43 (78.18) | ||
| Open | 27 (31.03) | 15 (46.88) | 12 (21.82) | ||
| Tumor number | 3.96 | 0.047 | |||
| Solitary | 75 (86.21) | 24 (75.00) | 51 (92.73) | ||
| Multiple (≥ 2) | 12 (13.79) | 8 (25.00) | 4 (7.27) | ||
| Maximum tumor diameter | 3.02 | 0.082 | |||
| < 5 cm | 32 (36.78) | 8 (25.00) | 24 (43.64) | ||
| ≥ 5 cm | 55 (63.22) | 24 (75.00) | 31 (56.36) | ||
| Preoperative tumor markers | 4.00 | 0.046 | |||
| Absent | 65 (74.71) | 20 (62.50) | 45 (81.82) | ||
| Present | 22 (25.29) | 12 (37.50) | 10 (18.18) | ||
| Microsatellite | 0.38 | 0.535 | |||
| Microsatellite stable | 81 (93.10) | 31 (96.88) | 50 (90.91) | ||
| Microsatellite instability | 6 (6.90) | 1 (3.12) | 5 (9.09) |
Table 6 Association between genetic mutations, clinicopathological features and prognosis (5-year survival), n (%)
| Variable | Total (n = 87) | Death (n = 51) | Survival (n = 36) | χ² value | P value |
| Gender | 8.74 | 0.003 | |||
| Female | 24 (27.59) | 8 (15.69) | 16 (44.44) | ||
| Male | 63 (72.41) | 43 (84.31) | 20 (55.56) | ||
| Age | 1.99 | 0.159 | |||
| < 60 years | 20 (22.99) | 9 (17.65) | 11 (30.56) | ||
| ≥ 60 years | 67 (77.01) | 42 (82.35) | 25 (69.44) | ||
| KRAS mutation | 12.69 | < 0.001 | |||
| Mutant | 39 (44.83) | 31 (60.78) | 8 (22.22) | ||
| Wild-type | 48 (55.17) | 20 (39.22) | 28 (77.78) | ||
| PIK3CA mutation | 2.56 | 0.110 | |||
| Mutant | 12 (13.79) | 4 (7.84) | 8 (22.22) | ||
| Wild-type | 75 (86.21) | 47 (92.16) | 28 (77.78) | ||
| FBXW7 mutation | 1.02 | 0.314 | |||
| Mutant | 24 (27.59) | 12 (23.53) | 12 (33.33) | ||
| Wild-type | 63 (72.41) | 39 (76.47) | 24 (66.67) | ||
| TP53 mutation | 0.14 | 0.707 | |||
| Mutant | 56 (64.37) | 32 (62.75) | 24 (66.67) | ||
| Wild-type | 31 (35.63) | 19 (37.25) | 12 (33.33) | ||
| Diabetes | 2.17 | 0.141 | |||
| Absent | 71 (81.61) | 39 (76.47) | 32 (88.89) | ||
| Present | 16 (18.39) | 12 (23.53) | 4 (11.11) | ||
| Hypertension | 3.28 | 0.070 | |||
| Absent | 48 (55.17) | 24 (47.06) | 24 (66.67) | ||
| Present | 39 (44.83) | 27 (52.94) | 12 (33.33) | ||
| Hyperlipidemia | 0.60 | 0.438 | |||
| Absent | 71 (81.61) | 43 (84.31) | 28 (77.78) | ||
| Present | 16 (18.39) | 8 (15.69) | 8 (22.22) | ||
| Smoking | 2.04 | 0.153 | |||
| Absent | 63 (72.41) | 34 (66.67) | 29 (80.56) | ||
| Present | 24 (27.59) | 17 (33.33) | 7 (19.44) | ||
| Alcohol use | 12.48 | < 0.001 | |||
| Absent | 62 (71.26) | 29 (56.86) | 33 (91.67) | ||
| Present | 25 (28.74) | 22 (43.14) | 3 (8.33) | ||
| Tumor location | 6.07 | 0.048 | |||
| Left colon | 21 (24.14) | 13 (25.49) | 8 (22.22) | ||
| Rectum | 46 (52.87) | 22 (43.14) | 24 (66.67) | ||
| Right colon | 20 (22.99) | 16 (31.37) | 4 (11.11) | ||
| Differentiation grade | 12.79 | < 0.001 | |||
| Well/moderate | 72 (82.76) | 36 (70.59) | 36 (100.00) | ||
| Poor | 15 (17.24) | 15 (29.41) | 0 (0.00) | ||
| Lymphovascular invasion | 5.09 | 0.024 | |||
| Absent | 51 (58.62) | 35 (68.63) | 16 (44.44) | ||
| Present | 36 (41.38) | 16 (31.37) | 20 (55.56) | ||
| Perineural invasion | 0.09 | 0.769 | |||
| Absent | 75 (86.21) | 43 (84.31) | 32 (88.89) | ||
| Present | 12 (13.79) | 8 (15.69) | 4 (11.11) | ||
| Preoperative pathology | 0.28 | 0.595 | |||
| Adenocarcinoma (non-special) | 82 (94.25) | 47 (92.16) | 35 (97.22) | ||
| Mucinous adenocarcinoma | 5 (5.75) | 4 (7.84) | 1 (2.78) | ||
| T stage | 5.17 | 0.023 | |||
| T1 + T2 | 5 (5.75) | 0 (0.00) | 5 (13.89) | ||
| T3 + T4 | 82 (94.25) | 51 (100.00) | 31 (86.11) | ||
| N stage | 17.02 | < 0.001 | |||
| N0 | 12 (13.79) | 0 (0.00) | 12 (33.33) | ||
| N1 + N2 | 75 (86.21) | 51 (100.00) | 24 (66.67) | ||
| M stage | 2.17 | 0.141 | |||
| M0 | 71 (81.61) | 39 (76.47) | 32 (88.89) | ||
| M1 | 16 (18.39) | 12 (23.53) | 4 (11.11) | ||
| Surgical approach | 2.23 | 0.136 | |||
| Laparoscopic | 60 (68.97) | 32 (62.75) | 28 (77.78) | ||
| Open | 27 (31.03) | 19 (37.25) | 8 (22.22) | ||
| Tumor number | 7.95 | 0.005 | |||
| Solitary | 75 (86.21) | 39 (76.47) | 36 (100.00) | ||
| Multiple (≥ 2) | 12 (13.79) | 12 (23.53) | 0 (0.00) | ||
| Maximum tumor diameter | 9.31 | 0.002 | |||
| < 5 cm | 32 (36.78) | 12 (23.53) | 20 (55.56) | ||
| ≥ 5 cm | 55 (63.22) | 39 (76.47) | 16 (44.44) | ||
| Preoperative tumor markers | 9.34 | 0.002 | |||
| Absent | 65 (74.71) | 32 (62.75) | 33 (91.67) | ||
| Present | 22 (25.29) | 19 (37.25) | 3 (8.33) | ||
| Microsatellite | 0.76 | 0.382 | |||
| Microsatellite stable | 81 (93.10) | 49 (96.08) | 32 (88.89) | ||
| Microsatellite instability | 6 (6.90) | 2 (3.92) | 4 (11.11) |
Table 7 Cox regression analysis of KRAS, PIK3CA, FBXW7, and TP53 gene mutation status along with other high-risk factors
| Variable | B | SE | Wald | df | Significance | Exp(B) | 95%CI for Exp(B) | |
| Lower bound | Upper bound | |||||||
| Gender | -1.219 | 0.476 | 6.542 | 1 | 0.011 | 0.296 | 0.116 | 0.752 |
| Age | -0.432 | 0.43 | 1.007 | 1 | 0.316 | 0.649 | 0.279 | 1.509 |
| KRAS mutant | 1.272 | 0.336 | 14.313 | 1 | < 0.001 | 3.567 | 1.846 | 6.893 |
| PIK3CA mutant | -1.345 | 0.532 | 6.391 | 1 | 0.011 | 0.26 | 0.092 | 0.739 |
| FBXW7 mutant | 0.619 | 0.397 | 2.423 | 1 | 0.12 | 1.857 | 0.852 | 4.046 |
| TP53 mutant | 0.516 | 0.337 | 2.344 | 1 | 0.126 | 1.676 | 0.865 | 3.246 |
- Citation: Zhao SQ, Luo ZF, Yang ZF, Zhang WS, Fu YM. Independent prognostic value of KRAS mutation in resected colorectal cancer based on multi-gene sequencing. World J Gastrointest Oncol 2026; 18(6): 117308
- URL: https://www.wjgnet.com/1948-5204/full/v18/i6/117308.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i6.117308